AirSculpt Technologies (AIRS) vs Starling Oncology (STLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Starling Oncology (STLN) has outperformed AirSculpt Technologies (AIRS) over the past year, losing 4.2% versus a loss of 83.9%. Over five years, STLN leads with a -55.3% price change compared with -95.1% for AIRS. Starling Oncology is the larger company by market cap ($306.0 million vs $43.7 million), about 7.0 times the size.
AirSculpt Technologies converts more of its revenue into profit, with a net margin of -7.7% versus -12.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIRS | STLN |
|---|---|---|
| Share price | $0.5907 | $3.00 |
| Market cap | $43.67M | $305.97M |
| 1-day change | -9.72% | -5.66% |
| YTD return | -70.17% | -15.73% |
| 1-year return | -83.86% | -4.15% |
| 5-year return | -95.10% | -55.29% |
| EPS (TTM) | $-0.12 | $-0.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $151.82M | $502.73M |
| Revenue growth (YoY) | -15.82% | +27.79% |
| Net income (latest FY) | $-11.67M | $-60.61M |
| Gross margin | 59.37% | — |
| Operating margin | -7.61% | -7.18% |
| Net margin | -7.68% | -12.06% |
| 52-week high | $5.79 | $7.13 |
| 52-week low | $0.516 | $2.32 |
| Distance from 52-week high | -89.80% | -57.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +661.81% | +208.33% |
| Average volume | 1.27M | 2.55M |
| Shares outstanding | 73.93M | 101.99M |
| Employees | 330 | 641 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Starling Oncology is about 7.0 times larger than AirSculpt Technologies by market value ($305.97M vs $43.67M).
- STLN has outperformed AIRS by 79.7 percentage points over the past year.
- Starling Oncology grew revenue faster in its latest fiscal year (+27.79% vs -15.82%).
About AirSculpt Technologies
AIRS stock →AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.
Health Care · Medical/Nursing Services · 330 employees
About Starling Oncology
STLN stock →Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Health Care · Medical/Nursing Services · 641 employees
AIRS vs STLN FAQ
Which is bigger, AirSculpt Technologies or Starling Oncology?
Starling Oncology (STLN) is larger, with a market capitalization of $305.97M compared with $43.67M for AirSculpt Technologies (AIRS).
Which stock has performed better over the past year, AIRS or STLN?
STLN returned -4.15% over the past 12 months, compared with -83.86% for AIRS (price return, excluding dividends). Past performance does not predict future results.
Are AirSculpt Technologies and Starling Oncology in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.